Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nonalcoholic steatohepatitis (NASH)
Biotech
Aligos MASH prospect slashes liver fat in phase 2
Aligos is heralding a mid-stage MASH win after its candidate slashed liver fat at three different doses. Still, investors weren't impressed.
Gabrielle Masson
Sep 19, 2024 1:00pm
Viking's MASH drug scores where Madrigal's didn't
Jun 4, 2024 1:51pm
Boehringer signs $1.3B MASH collab with RNA biotech Ochre
Apr 22, 2024 8:45am
Ascletis pulls FXR agonist from pipeline over phase 2 data
Apr 3, 2024 8:50am
Chinese biotech's MASH drug reduces liver fat in phase 2 trial
Mar 18, 2024 11:07am
Akero soars as liver scarring improves in longer MASH trial
Mar 4, 2024 6:30am
